PCI-27483
- Generic Name
- PCI-27483
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24N6O9S
- CAS Number
- 871266-63-6
- Unique Ingredient Identifier
- 6073LCU8U9
- Background
PCI-27483 has been used in trials studying the treatment of Pancreatic Cancer, Ductal Adrenocarcinoma, and Exocrine Pancreatic Cancer.
Study of Safety and Tolerability of PCI-27483 in Patients With Pancreatic Cancer Patients Receiving Treatment With Gemcitabine
Phase 2
Completed
- Conditions
- Pancreatic CancerDuctal AdrenocarcinomaExocrine Pancreatic Cancer
- Interventions
- First Posted Date
- 2009-11-25
- Last Posted Date
- 2014-04-24
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 42
- Registration Number
- NCT01020006
- Locations
- 🇺🇸
Park Nicollet Institute, St. Louis Park, Minnesota, United States
🇺🇸Space Coast Medical Associates, Titusville, Florida, United States
🇺🇸Columbia University, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath